Identification of neoantigens is a critical step in predicting response to checkpoint blockade
therapy and design of personalized cancer vaccines. This is a cross-disciplinary challenge …

Neoantigens are tumor-specific peptide sequences resulting from sources such as somatic
DNA mutations. Upon loading onto major histocompatibility complex (MHC) molecules, they …

Despite improved methods for MHC affinity prediction, the vast majority of computationally
predicted tumor neoantigens are not immunogenic experimentally, indicating that high …

Neoantigens are newly formed peptides created from somatic mutations that are capable of
inducing tumor-specific T cell recognition. Recently, researchers and clinicians have …

Background The use of next-generation sequencing technologies has enabled the rapid
identification of non-synonymous somatic mutations in cancer cells. Neoantigens are …

The remarkable clinical efficacy of the immune checkpoint blockade therapies has motivated
researchers to discover immunogenic epitopes and exploit them for personalized vaccines …

Current tumor neoantigen calling algorithms primarily rely on epitope/major
histocompatibility complex (MHC) binding affinity predictions to rank and select for potential …

Introduction The field of cancer therapy has undergone a major transformation in less than a
decade due to the introduction of checkpoint inhibitors, the advent of next generation …

Therapeutic cancer vaccines, an exciting development in cancer immunotherapy, share the
goal of creating and amplifying tumor-specific T-cell responses, but significant obstacles still …

Recent advances in immune checkpoint blockade therapy have revolutionized the treatment
of cancer. Tumor-specific antigens that are generated by somatic mutation, neoantigens, can …